LUPIN revenues grew 40.7% YoY to | 4439.4 crore (I-direct estimate: | 4652.8 crore) mainly due to 83.8% growth in US sales to | 2188.6 crore (I-direct estimate: | 2502 crore). Strong US sales were due to Gavis consolidation, robust sales in Metformin (anti-diabetic). Domestic sales grew 5.2% YoY to | 931.3 crore. (I-direct estimate: | 849.7 crore).EBITDA margins improved 333 bps YoY to 29.5% (I-direct estimate: 33.0%) mainly on account of a strong gross margin performance. EBITDA grew 58.6% YoY to | 1308.0 crore .Net profit grew 55.1% YoY to | 882.0 crore (I-direct estimate: | 930.4 crore) owing to a strong operational performance. ICICI Securities Limited remain upbeat about the FY18 prospects and maintain BUY with a target price of | 1890 based on 25xFY18E EPS of | 75.5.Trendlyne has 18 reports on LUPIN updated in the last year from 8 brokers with an average target of Rs 1773.9. Brokers have a rating for LUPIN with 5 price downgrades,2 price upgrades,1 upgrade in past 6 months and 1 downgrades,7 price downgrades,2 upgrades,4 price upgrades in past 1 Year.